AXELEAD Begins Operations
Takeda Pharmaceutical Company and Axcelead Drug Discovery Partners has announced the start of operations for...
Takeda and Sunovion have presented new evidence supporting the use of Latuda® (lurasidone), an atypical antipsychotic treatment for adults with schizophrenia, during multiple poster sessions at the 27th European College of Neuropsychopharmacology (ECNP).
New data presented support Latuda's short and long-term efficacy, as well as preventing relapse.
This new data also supports Latuda as a tolerable option for patients switching medication from risperidone, having a low propensity for weight gain with minimal effects on cardiovascular and metabolic parameters.
Download to find out more.
Takeda Pharmaceutical Company and Axcelead Drug Discovery Partners has announced the start of operations for...
Takeda Pharmaceuticals International and Sunovion Pharmaceuticals has announced the results from three post-hoc analyses evaluating...
Takeda Pharmaceutical Company today announced that a marketing authorisation application (MAA) has been submitted to...